Glioblastoma Vaccine Trial Moves Forward

Glioblastoma Vaccine Trial Moves Forward

The phase 2B SURVIVE trial testing SurVaxM, a cancer vaccine for glioblastoma, will continue as planned following an interim analysis showing sufficient promise to proceed. SurVaxM, combined with standard treatments like surgery, radiation, and chemotherapy, aims to extend survival and improve quality of life for patients with this aggressive brain cancer.

Viralgen, Trogenix collaborate on glioblastoma treatment

Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy toward clinical testing. Viralgen said it completed a batch of TGX-007 in less than a year using a good manufacturing practice, a series of protocols intended to ensure a product’s consistency and quality. Viralgen specializes in producing recombinant (human-made) adeno…

Viralgen and Trogenix to progress gene therapy for glioblastoma

Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.